Abstract: The invention relates to norcoclaurine synthases and substrate binding sites having one or more site-specific mutation which increase the activity, when compared to the wild type synthase, of the condensation of 4-HPAA and dopamine to (S)-norcoclaurine and/or 3,4-DhPAA and dopamine to (S)-norlaudanosoline. The inventors both identified specific mutations corresponding to at position 73, 75, 77, 82, 99, 114, 141, 142, 147, 152, 174 and/or 178 in the count according to SEQ ID No: 1, and sites corresponding to the binding domains defined in SEQ ID NO: 4 and 5, where the mutated increase of the activity may be positioned within these norcoclaurine synthases. These domains are conserved regions.
Type:
Grant
Filed:
June 18, 2018
Date of Patent:
January 21, 2025
Assignee:
RIVER STONE BIOTECH, INC.
Inventors:
Markus Schwab, Franziska Grassinger, Laura Occhipinti, Philipp Friedrich Berninger, Jon Richard Heal, Joseph Michael Sheridan, Anaelle Hatsch, Jens Houghton-Larsen
Abstract: Recombinant microorganisms, plants, and plant cells are disclosed that have been engineered to have reduced levels or activity of one or more alcohol dehydrogenases or aldehyde reductases thereby increasing the production of benzylisoquinoline alkaloids and/or benzylisoquinoline alkaloid precursors.
Type:
Grant
Filed:
June 18, 2021
Date of Patent:
April 23, 2024
Assignee:
RIVER STONE BIOTECH, INC.
Inventors:
Esben Halkjaer Hansen, Markus Schwab, Philipp Berninger, Fanny Delgrange, Franziska Grassinger